North America Smart Inhalers Market

The North America smart inhalers market is expected to reach US$ 3,749.90 Mn in 2027 from US$ 503.91 Mn in 2018. The market is estimated to grow with a CAGR of 25.7% from 2019-2027.

The growth of the market is driven by the factors such as, growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition. However, the market is likely to get impacted due to risks associated with cyber threats limited knowledge regarding the use of smart inhalers.

The cases of asthma and COPD has been increasing across the globe at a significant rate. During recent years, there has been rise in the number of smokers as well as air pollution in developed as well as developing countries. Asthma is a non-communicable disease categorized by recurrent attacks of breathlessness and wheezing, which differ in severity and frequency from person to person. While an asthma attack occurs, the lining of the bronchial tubes swells, affecting the airways to narrow, hence limiting the flow of air into and out of the lungs. Recurrent asthma symptoms frequently lead to feeling of daytime fatigue, sleeplessness, reduced activity levels and school and work absence. As per estimates provided by the WHO, there are currently 235 million people suffering from asthma across the globe. As per the Centers for Disease Control and Prevention (CDC), the number of adults above 18 years of age currently having asthma are approximately 19 million in the United States, accounting for almost 7.7% of the total adult population.

Similarly, there has been rising prevalence of COPD across the North America. Chronic obstructive pulmonary disease (COPD) is a progressive fatal lung disease that leads to breathlessness, leading to predisposes then exacerbations and later causes serious illness. As per the Global Burden of Disease Study report, a prevalence of around 251 million cases of COPD were recorded globally during the year 2016. It is estimated that globally approximately 3.17 million deaths were caused due to COPD during the year 2015, accounting for almost 5% of all deaths in 2015. The prevalence of COPD has been high in developed nations during the recent years. For instance, COPD is recognized as the third leading cause of death by disease in the United States. Approximately, 11 million individual are diagnosed with COPD. Hence, the rising prevalence of respiratory conditions such as asthma and COPD is anticipated to fuel the growth of the smart inhalers market across the globe at an exponential rate.

US is expected to lead the market in the North America region because the US has presence of various associations which provide help in the field of lung diseases. For instance, American Lung Association conducts research activities, education and training as well as undertakes initiatives to offer better treatment and support for the patients suffering with respiratory conditions such as asthma, COPD, influenza, lung cancer, pneumonia, and pulmonary fibrosis among others. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.

Mexico Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)

North America Smart Inhalers Strategic Insights

Strategic insights for the North America Smart Inhalers provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Smart Inhalers Report Scope

North America Smart Inhalers Regional Insights

The geographic scope of the North America Smart Inhalers refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

NORTH AMERICA SMART INHALERS – MARKET SEGMENTATION

By Product

• Inhalers
• Nebulizers

By Disorder

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End User

• Home-care Settings
• Hospitals & Clinics

By Geography

• North America

  • US
  • Canada
  • Mexico

Company Profiles

• GlaxoSmithKline plc
• Adherium Ltd.
• Vectura Group plc
• Novartis AG
• Findair Sp. z o. o.
• Cohero Health
• Crux Product Design Ltd
• Teva Pharmaceuticals
• 3M
• Amiko Digital Health Limited